Feasibility of Digital Thermal Monitoring to Assess Endothelium-Dependent Vasodilation in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

Not Applicable

Recruiting

Brief Summary: The Vendys II, an FDA-approved device, uses finger digital thermal monitoring (DTM) after a period of blood flow restriction to evaluate vascular health. This study will evaluate the feasibility of using this device to measure the Vascular Reactivity Index (VRI) in children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT).

Detailed Description: Primary Objective:

-Assess the feasibility of the use of VENDYS-II in children and AYA as a measure of vascular endothelial function, where feasibility is defined as completion of the evaluation by at least 70% of consented participants.

Secondary Objective:

-Summarize the incidence of any adverse events that precludes completion of assessment of endothelium-dependent vasodilation using the Vendys II in children and AYA.

Recruitment & Eligibility

Inclusion Criteria

Not provided

Exclusion Criteria

Any subject who does not consent/assent to participation.

-. Any subject with an injury or deformation to the index finger which prevents proper fit of the device.
Any subject with skin toxicity or neuropathy which prevents comfortable use of the device.

Arm && Interventions

Group	Intervention	Description
Vendys II Device	Vendys II Device	Your participation in this study will be over after your blood vessel health is measured 1 time with the Vendys II device

Primary Outcome Measures

Name	Time	Method
The use of VENDYS-II in children and AYA as a measure of vascular endothelial function.	through study completion, an average of 1 year

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial